Adel Toth
About Adel Toth
Adel Toth is a Senior Scientist in Discovery Research at Adaptimmune, with over ten years of experience in academic and industrial research. He specializes in developing novel immunotherapies for cancer through the use of genetically engineered T-cells.
Work at Adaptimmune
Adel Toth has been employed at Adaptimmune as a Senior Scientist in Discovery Research since 2021. In this role, Toth contributes to the development of novel immunotherapies for cancer, specifically focusing on genetically engineered T-cells. The position is based in Oxfordshire, England, where Toth applies extensive knowledge and skills in various research methodologies.
Education and Expertise
Adel Toth holds a Master’s Degree in Molecular Biology from the University of Szeged, completed between 2005 and 2010. Following this, Toth pursued a Doctor of Philosophy (Ph.D.) in Microbiology and Immunology at the same institution, graduating in 2015. Toth possesses over ten years of experience in both academic and industrial research environments, with expertise in tissue culture, primary cell isolation, cellular assays, multiparameter flow cytometry, and lentiviral transduction.
Background
Adel Toth has a strong academic foundation in the life sciences, having studied at the University of Szeged. The combination of a Master’s Degree in Molecular Biology and a Ph.D. in Microbiology and Immunology provides a solid basis for Toth's research work. This background supports Toth's current focus on cancer immunotherapy and the application of advanced cellular techniques.
Research Focus
In the role of Senior Scientist, Adel Toth focuses on the development of novel immunotherapies for cancer. This work involves the use of genetically engineered T-cells, which are designed to enhance the body's immune response against cancer cells. Toth's research contributes to advancing therapeutic strategies in oncology.